

Data Sharing Statement

WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med. DOI: 10.1056/NEJMoa2023184.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	After the trial has ended and its results have been reported, anonymized data sharing will occur as per the Policy Statement on Data Sharing by the World Health Organization (WHO)
Which data?	Anonymized data
Additional information about data	Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
How or where can the data be obtained?	To be provided later
When will data availability begin?	When final report is published
When will data availability end?	5 years after final report is published
Will any supporting documents be available?	Yes
Which supporting documents?	Study protocol
Additional information about supporting documents	—
How or where can supporting documents be obtained?	Protocol available at WHO website
When will supporting documents availability begin?	Protocol already available at WHO website
When will supporting documents availability end?	Access to protocol will be retained for at least 5 years from date of publication of this manuscript
To whom will data be available?	Proposals for access will be reviewed by the executive group of the international steering committee of the WHO Solidarity trial.
For what type of analysis or purpose?	Evidence synthesis/meta-analysis
By what mechanism?	By contacting corresponding author
Any other restrictions?	In line with WHO policy on data sharing in the context of public health emergencies
Additional information	—

This statement was posted on December 2, 2020, at [NEJM.org](https://www.nejm.org).